Dec 08, 2020
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
Nov 17, 2020
Immutep Announces Expansion of TACTI-002 Collaboration Trial
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development
Nov 08, 2020
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
Immutep Announces Australian Patent Grant for IMP701 Antibody
